[Anti-tumor effect of cytotoxic T lymphocytes induced by soluble antigen of ovarian carcinoma and anti-CD3 monoclonal antibody on ovarian carcinoma].
OBJECTIVE
To evaluate the therapeutic effect of the new method--adoptive cell immunotherapy on ovarian carcinoma.


METHODS
Tumor soluble antigen (TSA) was extracted from cells of ovarian carcinoma (COC1 and COC2n). To generate cytotoxic T lymphocytes (CTL), peripheral blood mononuclear cells (PBMC) collected from healthy persons were induced by TSA and anti-CD3 monoclonal antibody (CD3-McAb). The antitumor effect of CTL on COC1 cells in vitro was compared with LAK and CD3-AK, whereas the growth inhibitory effect of CTL on COC2n transplantation tumors in nude mice was compared with CD3-AK.


RESULTS
The cytotoxicity of CTL, CD3-AK and LAK was 79.4%, 52.1% and 51.7% respectively (P < 0.01). Mean volume of tumor in nude mice on the 9th day after ovarian carcinoma cells transplanted was 44.4 +/- 24.2 mm3 in CTL group, 118.8 +/- 40.0 mm3 in CD3-AK group and 443.0 +/- 158.7 mm3 in control (no treatment) (P < 0.01), whereas mean duration of survival was 28.5 days, 25.5 days and 17 days respectively (P < 0.01).


CONCLUSIONS
The results indicated that CTL exhibited higher cytotoxic effect in vitro and greater inhibitory effect on tumor growth resulting in longer survival in vivo. It suggested that the adoptive cell immunotherapy might provide a new idea for treatment of ovarian carcinoma.
Zhang
Q
Q
Department of Immunology, North China Coal Medical College, Tangshan.
Wan
Y
Y
Zhai
H
H
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology*; D017252:CD3 Complex / Q000276:immunology*; D003602:Cytotoxicity, Immunologic; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D007963:Leukocytes, Mononuclear / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D010051:Ovarian Neoplasms / Q000276:immunology / Q000473:pathology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D017252:CD3 Complex